Showing results (201-210 of 231) with videos related to
Sort By:
Pageof 24
The Australasian Journal of Dermatology|May 14, 2024
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patientsPeter Foley, Patrick D Mahar, Saxon D Smith, et al.The Journal of Clinical Endocrinology and Metabolism|December 9, 2014
Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologistsAnna L Mitchell, Linda Goss, Lemonia Mathiopoulou, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.Dermatology and Therapy|December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis CareBruce E Strober, Joelle M van der Walt, April W Armstrong, et al.The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.Frontiers in Neurology|September 30, 2021
Study Protocol for the Development of a European eHealth Platform to Improve Quality of Life in Individuals With Huntington's Disease and Their Partners (HD-eHelp Study): A User-Centered Design ApproachPearl J C van Lonkhuizen, Niko J H Vegt, Eline Meijer, et al.Dermatology and Therapy|June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment AdherenceJonathan I Silverberg, Alan D Irvine, Peter Foley, et al.Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.Journal of the American Academy of Dermatology|April 5, 2023
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areataCheng Zhou, Xiumin Yang, Bin Yang, et al.Pageof 24